Business Context and Reporting Period
This Form 8-K was filed by Ocuphire Pharma, Inc. on April 28, 2022. The registrant is a Delaware corporation with its principal executive offices in Farmington Hills, Michigan. Its common stock trades on the Nasdaq Capital Market under the symbol OCUP. The filing reports on a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a Current Report regarding a specific event and does not contain financial statements or quantitative financial data.
Material Changes and Events
Under Item 8.01 (Other Events), the Company reported the issuance of a press release on April 28, 2022, detailing the results of its MIRA-4 pediatric safety trial. The trial focused on the reversal of mydriasis. The full press release is included as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclaimer that website references in the press release are not incorporated by reference. The primary focus is the clinical trial result announcement.
Investor Verification Checklist
- Verify the specific clinical outcomes and safety data from the MIRA-4 pediatric trial by reviewing Exhibit 99.1 (Press Release).
- Confirm the current trading status and price of OCUP on the Nasdaq Capital Market following the announcement.
- Review the Company's most recent 10-Q or 10-K filing for actual financial metrics, as this 8-K contains none.
- Assess the potential regulatory implications of the pediatric safety trial results for the Company's product pipeline.